181 related articles for article (PubMed ID: 37873756)
21. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
García E; Ayoub N; Tewari KS
J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
[TBL] [Abstract][Full Text] [Related]
22. New pharmacotherapy options for cervical cancer.
Dueñas-Gonzalez A; Cetina L; Coronel J; Cano C; Dolores R
Expert Opin Pharmacother; 2014 Jan; 15(1):51-60. PubMed ID: 24206031
[TBL] [Abstract][Full Text] [Related]
23. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
[TBL] [Abstract][Full Text] [Related]
24. New approaches to high-risk cervical cancer. Advanced cervical cancer.
Jones WB
Cancer; 1993 Feb; 71(4 Suppl):1451-9. PubMed ID: 8431879
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
26. Advances in immunotherapy for cervical cancer.
Wendel Naumann R; Leath CA
Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
[TBL] [Abstract][Full Text] [Related]
27. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
29. Tailored radical hysterectomy for locally advanced cervical cancer.
Sakuragi N; Kaneuchi M; Kato T; Shimada C; Todo Y; Ihira K; Nozaki A; Umazume T; Konno Y; Mitamura T; Kobayashi N; Murakami G; Watari H
Int J Gynecol Cancer; 2020 Aug; 30(8):1136-1142. PubMed ID: 32522774
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant platinum-based chemotherapy for early stage cervical cancer.
Rosa DD; Medeiros LR; Edelweiss MI; Bozzetti MC; Pohlmann PR; Stein AT; Dickinson HO
Cochrane Database Syst Rev; 2009 Jul; (3):CD005342. PubMed ID: 19588370
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of the patients with locally advanced stages I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy.
Namkoong SE; Park JS; Kim JW; Bae SN; Han GT; Lee JM; Jung JK; Kim SJ
Gynecol Oncol; 1995 Oct; 59(1):136-42. PubMed ID: 7557599
[TBL] [Abstract][Full Text] [Related]
32. Management of locally advanced cervical cancer.
Rojas-Espaillat LA; Rose PG
Curr Opin Oncol; 2005 Sep; 17(5):485-92. PubMed ID: 16093801
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
34. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy and immune check point inhibitors in the management of cervical cancer.
Kumar L; Upadhyay A; Jayaraj AS
Curr Probl Cancer; 2022 Dec; 46(6):100900. PubMed ID: 36265252
[TBL] [Abstract][Full Text] [Related]
36. Tisotumab Vedotin: First Approval.
Markham A
Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
Agostinelli V; Musacchio L; Camarda F; Salutari V; Carbone MV; Ghizzoni V; Nero C; Ricci C; Perri MT; Giudice E; Lardino S; Berardi R; Scambia G; Lorusso D
Cancer Manag Res; 2023; 15():1063-1072. PubMed ID: 37790898
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant therapy in cervical cancer patients with high risk factors.
Park TK
Yonsei Med J; 1997 Oct; 38(5):255-60. PubMed ID: 9409188
[TBL] [Abstract][Full Text] [Related]
40. Emerging drugs for the treatment of cervical cancer.
Serrano-Olvera A; Cetina L; Coronel J; Dueñas-González A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):165-82. PubMed ID: 25578210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
